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Abstract
Background: In 1982 Smith and Huggins showed that bacteriophages could be at least as effective
as antibiotics in preventing mortality from experimental infections with a capsulated E. coli (K1) in
mice. Phages that required the K1 capsule for infection were more effective than phages that did
not require this capsule, but the efficacies of phages and antibiotics in preventing mortality both
declined with time between infection and treatment, becoming virtually ineffective within 16 hours.
Results:  We develop quantitative microbiological procedures that (1) explore the in vivo
processes responsible for the efficacy of phage and antibiotic treatment protocols in experimental
infections (the Resistance Competition Assay, or RCA), and (2) survey the therapeutic potential of
phages in vitro (the Phage Replication Assay or PRA). We illustrate the application and utility of
these methods in a repetition of Smith and Huggins' experiments, using the E. coli K1 mouse thigh
infection model, and applying treatments of phages or streptomycin.
Conclusions: 1) The Smith and Huggins phage and antibiotic therapy results are quantitatively and
qualitatively robust. (2) Our RCA values reflect the microbiological efficacies of the different phages
and of streptomycin in preventing mortality, and reflect the decline in their efficacy with a delay in
treatment. These results show specifically that bacteria become refractory to treatment over the
term of infection. (3) The K1-specific and non-specific phages had similar replication rates on
bacteria grown in broth (based on the PRA), but the K1-specific phage had markedly greater
replication rates in mouse serum.
Background
Mounting concerns about drug-resistant pathogenic bac-
teria [1–3] have rekindled interest in alternative treat-
ments of bacterial infections. Prominent among these
alternatives is phage therapy, the use of bacteriophages to
kill or otherwise control the bacterial populations in in-
fected hosts. The use of bacteriophage for the treatment of
bacterial infections is an old idea [4] that not only caught
the imagination of at least one novelist [5] it was practiced
with sporadic successes worldwide in the 1920s and
1930s. However, following the development of antibiot-
ics in the 1940s, the use of phages to treat and prevent in-
fections disappeared from so-called Western Medicine,
but it did survive in the former Soviet Union. A rekindled
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interest in phage therapy over the past decade has inspired
historical reviews, increased our awareness of a substan-
tial body of phage therapy work from Eastern Europe [6–
8], resulted in the West's "discovery" of the Eliava Institute
(a one-time vast and thriving phage therapy research and
production facility in Tiblisi, Georgia [9]), and motivated
the formation of companies developing phage therapy
(Biophage Inc. of Montreal, Canada; Exponential Biother-
apies Inc. of Port Washington, NY; Intralytix of Baltimore,
MD). In recent years this renewed interest in phage thera-
py has been displayed in articles in the popular press,
(e.g., Kuchment 2001, Superbug Killers, News Week, Dec.
17, 2001 50–51) and, of course, reviews and discussions
on the internet,  [http://www.phage.org];  [http://www.ev-
ergreen.edu/user/T4/PhageTherapy/Phagethea.html].
Renewed interest in phage therapy is also evident from re-
cent empirical studies of phage therapy [10–15] and the-
oretical excursions into the population dynamics of phage
therapy [16,17]. This rebirth has also revived attention to
earlier experimental work on phage therapy and prophy-
laxis, including several impressive studies using phage to
treat and prevent bacterial infections in mice, calves, pig-
lets and lambs by H. Williams Smith, M.B Huggins and
their colleagues [18–20].
The earliest of the Smith and Huggins studies [18] is espe-
cially instructive in this light. Using experimental, lethal
infections of an E. coli 018:K1:H7 into the mouse thigh, it
showed: (i) phage were at least as effective as antibiotics
in preventing mouse mortality; (ii) not all phages were
equally useful, rather those that required the K1 antigen
for infection were superior to phages not requiring K1;
(iii) survival declined with a delay in treatment, even
though the treatment was applied well before untreated
mice had overt symptoms of the infection. Perhaps most
importantly, Smith and Huggins [18] also provided infor-
mation about the dynamics of phage treatment – the
changes in bacterial and phage densities over the course of
the infection. Ultimately, the efficacy of antibacterial ther-
apy has to be measured by the rate at which it eliminates
the symptoms of the infection. Microbiological data on
the course of infections with and without treatment – the
population dynamics of the treatment process – provide a
means to understand how treatment operates and allows
one to compare, modify and improve therapeutic proto-
cols.
The present study is offered in the spirit of continuing the
precedent set by Smith and Huggins for analyzing the
population dynamics of phage and antibiotic therapy. We
use their infection model to develop and illustrate the use
of two quantitative methods that facilitate understanding,
comparing and developing methods of antibacterial ther-
apy and protocols for their application. One method pro-
vides a facile measure of efficacy of treatment that is
independent of the clinical outcome of infection and can
be applied on a tissue- and time-specific basis for any
form of treatment to which bacteria can acquire resist-
ance. The other method is a simple procedure to assay
phage growth rate in vitro that can be used to screen phag-
es to evaluate their potential for therapy.
Results
Smith and Huggin's results are repeatable
We repeated the experiments of H. William Smith and
M.N. Huggins [18]. Despite the fact that we used different
sources of mice, E. coli 018:K1:H7, bacteria and phages,
our treatment and mortality rate results were similar to
theirs both qualitatively and quantitatively (Fig. 1):
(a) All 15 untreated/control mice died within 40 hours of
inoculation with CAB1. All 15 mice survived when treated
immediately with φLH (the phage requiring the bacterial
K1 antigen for adsorption) or when treated immediately
with a single dose of 60 µg/gm streptomycin. In contrast,
only 6 of the 15 mice survived when treated immediately
with φLW (the phage that was not specific for the K1-cap-
sule). These results closely match those of Smith and Hug-
gins [18], except that they did not report experiments of
immediate treatment with streptomycin or other antibiot-
ic.
(b) Even though mice with untreated infections normally
survived at least 24 hours, delaying treatment for only 8
hours significantly reduced the rate of survival of mice
treated with a single dose of 60 µ/gm and of 100 µ/gm
streptomycin. The survival rate of these streptomycin-
treated mice, however, significantly exceeded that of the
controls and that which Smith and Huggins [18] obtained
with a single dose of 25 µ/gm streptomycin. The survival
of mice treated with φLH was slightly reduced with de-
layed treatment (11 of the 12 mice treated at 8 hours sur-
vived, versus 15 out of 15 with immediate treatment), a
difference that is not statistically significant. In the Smith
and Huggins study, the decline in survival at 8 hours was
significant for the combined samples of 9 isolates of K1-
specific phages, but not for their most efficacious phage.
We did not conduct delayed treatment experiments with
φLW or with multiple doses of streptomycin.
The Resistance Competition Assay (RCA)
Derivation
The principle of this method is that, when a mixture of re-
sistant and sensitive cells is treated, the relative frequency
of bacteria resistant to treatment will increase at a rate ac-
cording to efficacy of the treatment. That is, resistant cells
increase relative to sensitive cells by the amount that treat-
ment kills or inhibits sensitive bacteria. The derivation of
our measure of this efficacy of treatment, RCA, followsBMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/35
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from standard population genetics models of selection
between two haploid genotypes that different in their rel-
ative fitness [21]. (Following convention, we use italicised
RCA for the parameter value or estimate, and normal font
RCA for the assay procedure.) In this perspective, sensitive
and resistant bacteria are the two competing genotypes.
The RCA estimates the relative fitness advantage (or disad-
vantage) of the resistant bacteria over sensitive bacteria. In
situations where one has the luxury of many sampling
points, an RCA can be calculated from the slope of the
natural log of the ratio of the densities of Resistant/Sensi-
tive as a function of time [22]. In situations where only
two points are feasible, the initial frequency of resistant
bacteria in the inoculum (p0) and the frequency of resist-
ant bacteria at time t (pt) an RCA can be calculated from
RCA = ln [(pt (1-p0))/(p0(1-pt))]/t   (1)
(for the derivation see Crow and Kimura [21]).
The value of RCA is the selection coefficient of resistant
cells (in the vernacular of population genetics). If RCA > 0
then the resistant cells have an advantage, if RCA < 0, the
resistant cells are at a selective disadvantage. RCA operates
on an exponential scale:
pt/(1-pt) = etRCA (p0/(1-p0).   (2)
If the differential success of sensitive and resistant cells is
constant over time, then the ratio of resistant to sensitive
cells increases by a factor of eRCA every hour (unit of t). As-
suming that cells are not growing and that treatment kills
sensitive cells, an RCA of 0 means that sensitive cells are
not killed, an RCA of 1 means that 63% of sensitive cells
are killed per hour (95% in 3 hours), and an RCA of 2
means that 86.5% of sensitive cells are killed per hour
(99.8% in 3 hours). If the process is not constant, then the
RCA  is an average over the interval of estimation and
should not be projected to longer intervals; however, esti-
mations of RCA at different times would reveal how treat-
ment efficacy is changing with time.
As an alternative to using the initial frequency of resistant
cells as the estimate of p0, one can substitute the final fre-
quency (qt) of resistant bacteria in untreated controls (as
was done here). This substitution controls for intrinsic dif-
ferences in fitness of the two bacteria, for differences in the
physiological states of the bacteria at the time of inocula-
tion that could affect their growth rates independent of
treatment, and for possible differences in the host re-
sponse with and without treatment. The resulting RCA is
thus the advantage of resistant cells over sensitive cells rel-
ative to their advantage in the absent of treatment. For ex-
ample, in the absence of antibiotic treatment, resistant
bacteria may have a disadvantage in competition with
sensitives [23], and use of qt in place of p0 will correct for
this effect. It is important, however, that the controls from
which qt is obtained be inoculated with the same mix of
bacteria and be sampled at the same times as the treated
mice.
Bacteria become refractory to phage and antibiotics within 8 hours
As noted in Figure 1 and in more detail in [18–20], the
survival rate from treatment with phage and antibiotics
declines dramatically with the term of infection. A declin-
ing efficacy of delayed treatment is also evident by com-
Figure 1
Survival of CAB1 infected mice: (Top) Immediate Treatment
– Mice were inoculated with 108 CAB1 in the right thigh and
within one minute treated by inoculation in the left thigh with
(i) a control (saline or a CAB1-pseudolysate) (ii) 108 non-K1
specific phage φLW, (iii) 108 K1-specific phage φLH, or (iv) 60
µg/ml streptomycin. (Bottom) Delayed Treatment: – Mice
were inoculated with 108 CAB1 in the right thigh and, 8
hours later, treated by inoculation in the left thigh with (i)
0.85% saline (control), (ii) 108 K1-specific, φLH, phage, (iii) 60
µg/gm streptomycin, or (iv) 100 µg/ml streptomycin.
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paring RCA values for φLH or streptomycin (Table 1). The
RCA  for a single dose of streptomycin was 2.1 after imme-
diate treatment but declined to 0.5 when treatment was
delayed 8 hours. The corresponding values for the K1-spe-
cific phage were 1.7 and 0.3. The RCA for φLH at 8 hours
is statistically indistinguishable from that for immediate
treatment with φLW (0.2), even though the mouse surviv-
al under these two conditions differs significantly (Fig. 1;
P < 0.02). It is thus evident that by eight hours the bacteria
had declined in their susceptibility to phage, and antibiot-
ic efficacy declined as well. It is noteworthy that there were
no apparent clinical symptoms of these infections at 8
hours (or even at 12 hours).
The bacteria inoculated into the thigh not only became re-
fractory to antibiotic and phage treatment within a few
hours after inoculation, they persisted and remained re-
fractory to phage treatment for a number of days if the
mouse survived. In samples taken 7 days after treatment,
the density of the φLH phage in the thigh was 109 phage
particles per gram, and while phage resistant cells were
present, 80% (0.81 ± 0.01) of the bacteria isolated from
leg tissue remained sensitive to this phage.
The Phage Replication Assay: phages φLW and φLH have 
similar growth rates in broth but not serum
Mortality rates of mice in Smith and Huggins [18] and
here, as well as the RCA values, indicate that phages spe-
cific for the K1-capsule are more effective in controlling
the infections than phage that are not specific for the cap-
sule. Could this have been anticipated from the in vitro
capacity of the phage to replicate on and kill E. coli
018:K1:H7? The Phage Replication Assay (PRA) attempts
to provide a measure of in vitro efficacy that can be ex-
tended to in vivo performance. The rate of doubling of a
population of lytic phage on a population of bacteria
measures the ultimate efficacy of that phage in killing
those bacteria. This overall replication rate depends on ad-
sorption rate, latent period, and burst size on that bacteri-
al host, as well as temperature and other physical
properties of the culture conditions (see Additional file 1).
The rate of replication also depends on the ratio of phage
to bacteria (the multiplicity of infection) and most criti-
cally on the density and physiological state of the bacterial
population [24,25]). Despite the many factors that influ-
ence phage replication rates (and hence influence the PRA
value), these factors are easily controlled, and further-
more, the comparison of PRAs between different phages is
straightforward if the PRAs are obtained from common
bacterial cultures (as here, see Methods).
Our PRA values are surprising in some respects yet are
consistent with the mouse mortalities and microbiologi-
cal data. When the PRA of these phage were estimated on
cells grown in Luria Broth, there was no apparent differ-
ence between the two phages (Fig. 2); the PRAs were
strongly affected by cell densities, but both phages
showed similar patterns, and there is no basis from these
in vitro data for suggesting any difference in their efficacy
at replication on and killing CAB1. Note that the observed
PRAs declined with increasing bacterial density, the oppo-
site of the effect seen in the simulations of Additional file
1. There are in fact two opposing effects of cell density on
the PRA. One is that higher cell densities reduce phage
generation time by decreasing the time for a phage to en-
counter a host. This increases the PRA. The other is that
high cell densities exhaust nutrients in the media and
thereby slow bacterial growth, in turn reducing phage me-
tabolism and thus reducing the PRA. Only the former ef-
fect was considered in the model of Additional file 1.
When the PRA was estimated on cells grown in mouse se-
rum, the K1-specific phage φLH had a much higher rate of
replication than φLW (Fig. 2). Despite variance in the esti-
mates, there was a pronounced superiority of the K1-spe-
cific phage φLH over the non-specific phage φLW.
Although this serum assay did not fully mimic in vivo
growth conditions, it certainly supports the hypothesis
that the greater treatment efficacy of φLH is specific to
Table 1: Resistance Competition Assay comparison of treatment 
factors
RCA value
Treatment Immediate Delayed
φLH-Phage 1.7 ± 0.14 0.3 ± 0.13
streptomycin 2.1 ± 0.12 0.5 ± 0.10
φLW-Phage 0.2 ± 0.07 not assayed
Resistance Competition Assay (RCA) of bacteria from the infected 
legs of mice sampled 3–4.5 hours after treatment of CAB1 infections 
(mean ± 1 std error). Bacterial resistance was specific to the treat-
ment, phage or streptomycin. Immediate treatment was delivered at 
the same time as the bacterial inoculation; delayed treatment was 
delivered 8 hours after inoculation. For treatment with streptomycin 
and φLH-phage, resistant bacteria have significantly higher RCA values 
with immediate treatment than with delayed treatment (t-tests, P < 
0.002 for φLH-phage; P < 0.005 for streptomycin). With immediate 
treatment, RCA values of resistant bacteria are significantly higher both 
for streptomycin and φLH than for φLW (P < 0.005 and P < 0.01, 
respectively), but the difference between immediate treatment with 
streptomycin and φLH is not significant (0.05 < P < 0.10). An RCA 
value of zero indicates that resistant bacteria have no advantage over 
sensitive bacteria, hence that treatment is presumably ineffective in 
killing bacteria in the leg; presumed treatment efficacy increases as the 
RCA increases above zero. Treatment doses were ~108 phage/mouse 
or 100 µg/gm streptomycin sulfate via an intramuscular injection into a 
limb. Frequencies of sensitive and resistant bacteria were estimated as 
in Methods.BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/35
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phage replication on bacteria in mice and is not from a
general superiority of φLH.
Discussion
Our goal here was to develop procedures to explore the
dynamical underpinnings of success and failure in treat-
ing bacterial infections. To illustrate the application of
these procedures, we used the E. coli K1 mouse thigh in-
fection model of Smith and Huggins [18], and like them,
applied treatments of phages and antibiotics. As part of
this effort, we repeated their experiments to ascertain if
their results were robust. Across a variety of treatments
and conditions, mouse mortality rates were remarkably
similar between our study and theirs, even though we
used a different strain of mice, phages from different
sources, and an independently isolated strain of E. coli
018:K1:H7. Thus, in the absence of treatment, inocula-
tions of 108 bacteria were fatal in over 95% of mice, but
immediate treatment with phage that were specific for the
K1 capsule or with streptomycin essentially eliminated
mortality from the infection. Immediate treatment with
phages that were not specific for the capsule also reduced
mortality, but mortality rates for treatment with these
phage were greater than with the K1-specific phage. Both
studies also observed that mortality increased if treatment
was delayed by 8 hours, under most forms of treatment.
Factors affecting treatment success
Two observations from these combined studies seem es-
pecially interesting. (i) Phages vary in treatment success.
(ii) Delaying treatment by 8 hours substantially increases
the rate of mortality relative to that of immediate treat-
ment (for many of the treatments applied here), despite
the fact infected mice survive at least 16 hours longer. In
attempting to better understand these observations, we
developed two assays. One assay, the RCA (Resistance
Competition Assay) measures the efficacy of a treatment
in killing or inhibiting the growth of bacteria based on
changes in the frequency of treatment-resistant bacteria
after treatment is applied. The other assay, the PRA (Phage
Replication Assay), measures the ability of a phage to rep-
licate on populations of a bacterium under controlled, in
vitro conditions.
The RCA and PRA values reflect what is observed with oth-
er (microbiological) measures of the efficacy of treatment.
Consider first the effect of delayed treatment, which re-
duced mouse survival in most treatments. Increased mor-
tality with delayed treatment could have various causes:
(i) By the time of treatment, the numbers of bacteria are
already sufficiently high that mortality is caused by toxins
and tissue damage ensuing from them, rather than from
further growth of the bacteria. Under these conditions, re-
ducing the number of bacteria by treatment would have
little effect on the clinical outcome of the infection. (ii) By
the time of treatment, the numbers of bacteria are so high
that the mouse's defenses cannot prevent further growth
of the bacterial population, even with treatment, and bac-
terial numbers simply increase to the point of mortality.
This model is similar to that in (i), except that a treatment
which controlled bacterial growth would prevent mortal-
ity. (iii) As a consequence of the host's response to the
proliferating population of bacteria, the site of the infec-
tion becomes less accessible to the antibiotic or phages,
and the proliferation of the bacterial population can no
longer be controlled by these antibacterial treatments. (iv)
The bacteria become physiologically refractory to the
treatment.
The RCA specifically supports the latter two models. If by
eight hours the bacteria were as accessible and responsive
to the phage or antibiotic as they were initially, the RCA
values would remain high. We instead observed a drop in
RCA values. The data do not rule out additional processes
consistent with models (i) or (ii), but the data clearly re-
veal a reduced bacterial susceptibility or reduced access of
treatment to the bacteria when treatment is delayed.
Figure 2
Phage Replication Assay: Rate of replication of φLH and φLW
on CAB1 in LB and in mouse serum. In LB, the growth rates
of the K1 phage (φLH, squares connected by the solid line)
are similar to those of the non-K1 phage (φLW, solid circles
connected by the dashed line) across a range of densities,
with both phages growing more rapidly on cells at low den-
sity than on cells at high density, near saturation. However,
on cells grown in mouse serum, the growth rate is much
higher for the K1-specific phage, φLH, (gray triangles) than
for the non-K1 specific phage, φLW (gray circles). Growth
rate is presented as doublings of phage concentration per
hour; standard error bars are given for each black point (on
the lines), but most are so short as to be obscured by the
point. Each gray point represents one assay in serum.
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More than a half a century ago, H. Eagle and colleagues
observed a dramatic decline in the efficacy of antibiotics
with the term of the infection in a mouse thigh model. In
their now classical investigations of the within-host dy-
namics of antibiotic treatment, they followed the course
of penicillin treatment of Treponema pallidum and Group
A and Group B Streptococcus [26–28]. Eagle [28] postu-
lated that the most likely reason for the declining efficacy
of treatment with the term of the infection was due to (i)
a decline in the rate of metabolism and replication of bac-
teria during the infection, and (ii) that slowly growing or
non-growing bacteria are more refractory to penicillin
than those that replicating at higher rates. More recent
work by E. Tuomanen, A. Tomaz and their colleagues sup-
ported this interpretation, a phenomenon they called
phenotypic tolerance [29–31]. They also provided evi-
dence that nutrient limitation was the cause of the decline
in the rate of bacterial growth [32]. Not only do bacteria
become increasingly refractory to the majority of antibiot-
ics as their rate of growth declines, but they also adsorb to
and replicate bacteriophage less efficiently [24,33], as is
evident from the PRA values in Fig. 2. Thus the decline in
the efficacy of phage and antibiotic therapy with delayed
treatment in our experiments is plausibly attributed to a
decline in the rate of replication of E. coli K1 once inside
the mouse.
The other intriguing observation from Smith and Huggins
that we corroborated here is the consistent superiority of
phages requiring the K1 antigen for infection, when meas-
ured as mouse survival. Our RCA values showed a signifi-
cant difference between the phages in vivo, suggesting that
the K1-specific phages replicate at a higher rate than the
non-K1-specific phages inside the mouse. Yet although
Smith and Huggins casually observed that their non-K1-
specific phages were inferior to K1-specific phages at lys-
ing cultures of bacteria grown in artificial media, suggest-
ing intrinsic differences between the phages more
generally, our PRA estimates indicated that there was no
intrinsic difference between our two phages in artificial
media. Instead PRA  differences were consistent with
mouse survival and RCA data only when the PRA was
measured on cells grown in mouse serum. Thus the PRA
enables one to begin unravelling the environmental bases
of differences in phage growth in vivo.
In this investigation, we used the mouse thigh infection
model because of the many precedents for its use and be-
cause of its established repeatability [34–37]. The fact that
bacteria undergo such a profound change in susceptibility
or accessibility to treatment in only 8 hours raises the
question of whether the mouse thigh infection model is
representative of natural infections. This question is not
necessarily answerable at present, but the results do high-
light the fact that development of specific protocols and
phages for treatment in any one experimental model may
be inadequate for treatment of the same bacterium under
field conditions.
The Resistance Competition Assay
The preceding discussion indicates that the resistance
competition assay is consistent with other measures of
phage performance in vivo and provides specific insights
not easily obtained in other ways. The RCA has other vir-
tues that make it useful for studying phage therapy and
other forms of treatment. (1) It is versatile. In addition to
being used to study the population dynamics of phage
and antibiotic treatment in general, the RCA could be em-
ployed to design and evaluate the efficacy of different an-
tibiotic treatment protocols. It can be applied to virtually
any experimental model, such as enteric infections
[38,39] or urinary tract infections [40]. (2) The RCA pro-
vides a more direct measure of the in vivo action of anti-
biotics (or other treatments) than estimates of the
concentrations of these compounds in serum or in solid
tissue. Moreover, the RCA protocol controls for the contri-
bution of the host defenses as well as variety other factors
that could influence the density of bacteria in a particular
tissue. Only the action of the treatment per se can account
for the difference in the frequency of resistant bacteria be-
tween treated and untreated treated hosts. (3) The RCA is
more humane and offers greater statistical power (per an-
imal) than "outcome" measures of the efficacy of treat-
ment based on survival or other clinical indications. The
fact that the RCA yields a continuous statistic, rather than
a binary one, enables the use of standard statistical analy-
ses in which meaningful comparisons can be made with
as few as two replicates per group. (4) The RCA can be ap-
plied to populations of bacteria infecting specific tissues at
specific times, even allowing multiple measures per ani-
mal. However, individual tissues subjected to the RCA
must not have high levels of bacterial migration from oth-
er tissues over the course of treatment.
The RCA is a sensitive and specific measure of treatment
efficacy, and as such, will not correlate perfectly with other
measures of treatment. To wit, our RCAs were similar be-
tween delayed φLH treatment (0.3) and immediate φLW
treatment (0.2), even though mouse survival rates were
significantly different between them (11 of 12 mice versus
6 of 15). These discrepancies highlight the complexity of
the infection process and the fact that different measures
of infection dynamics capture different properties. Be-
cause our RCAs were based on samples from the infected
thigh, the values apply specifically to that thigh and do
not necessarily reflect the efficacy of treatment in other tis-
sues that may influence host survival.BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/35
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The Phage replication assay
This method has a potential utility beyond that demon-
strated here. If phage therapy is to be developed for partic-
ular infections, it would be useful to have an in vitro
procedure to screen phages for their potential efficacy in
vivo. The diversity of phage is enormous. For example
among 40 phage isolated from different samples or differ-
ent plaques on lawns of E. coli K12 and E. coli B, at least
32 distinct phage were found [41] (as measured by host
range and/or restriction pattern). A far greater number of
phage could certainly be isolated with a broader array of
lawn bacteria and by sampling different sources. The im-
plication is that it should be possible to isolate a substan-
tial number of lytic phage capable of killing most strains
of enteric and other bacteria, hence offering a compelling
reason to pursue phage therapy as a solution to antibiotic
resistance. Screening many phages for their therapeutic
potential in experimental animals would be a time- and
animal-consuming task. The PRA employed here could fa-
cilitate that screening. Our results suggest that phage per-
formance in serum could be a sufficient indicator of in
vivo performance, but there is no reason that this assay
could not be performed in vitro with other modifications,
such as solid tissues. Moreover, as suggested in a recent
study [12], in vivo culture may selectively improve the ca-
pacity of a phage to replicate on and kill bacteria in a
mammalian host.
Prospects for phage therapy
This is a methodological study to develop and experimen-
tally evaluate procedures to measure the efficacy of anti-
bacterial treatment and to screen bacteriophage for their
therapeutic potential. Our purpose in performing these
experiments and publishing these results is not to advo-
cate the use of phages for the treatment of systemic infec-
tions. Nevertheless, because of the current novelty of and
aspirations for phage therapy as an alternative to antibiot-
ics, it seems appropriate to acknowledge that our results
and those of several other studies offer promise that phage
therapy is highly repeatable, can be successful, and is thus
worthy of further research for clinical practice. Moreover
the use of phage for therapy and prophylaxis needn't be
restricted to humans, as phage could obviously be used
for these purposes in domestic animals.
There are, of course, a number of problems associated
with the use of phage as an alternative to antibiotics. To us
the most serious biological problem is a restricted host
range. Not only would one have to know the species of
bacteria responsible for an infection, it would be neces-
sary to know which phages can infect that strain of bacte-
ria. These requirements are certainly inconsistent with
current empiric therapy that uses broad spectrum antibi-
otics, which dominates how antibiotics are employed in
the community as well as in hospitals. Commonly, it is
not clear whether a bacterial infection is responsible for
the symptoms being treated with antibiotics, much less
the species, strain, and resistance profile of the bacteria re-
sponsible. On the other hand, there are situations, like ep-
idemics, where this knowledge would be available. And as
procedures to identify the bacteria responsible for symp-
tomatic infections get better and more rapid, it soon may
be quite easy to get this information from individual pa-
tients. As a consequence of the ever increasing frequency
of antibiotic resistant bacteria, the range of antibiotics to
which individual bacteria are resistant, and the limited
number of targets to which current (and soon to be antic-
ipated) antibiotics are directed, there is a pressing need to
develop alternative methods of treating and preventing
bacterial infections. Phages certainly offer some of the
most readily-available and promising alternatives.
Conclusions
(1) The results of the Smith and Huggins 1982 study of
phage and antibiotic therapy [18] are repeatable and ro-
bust quantitatively as well as qualitatively. Using their al-
most invariably (more than 95%) lethal E. coli K1 mouse
thigh infection protocol, but with different strains of mice
and independently isolated phages and bacteria, we ob-
tained the same frequencies of treatment survival as they
did. As they also observed, phages that required the K1
capsule for infection provided greater mouse protection
than phages that did not require K1. When treatment was
administered within minutes of the infection, both the K1
specific phage and single doses of streptomycin complete-
ly prevented infection-induced mortality. If, however,
treatment was delayed by eight hours, the rate of recovery
with a single dose of streptomycin (the most effective an-
tibiotic in the Smith and Huggins study) was reduced by
approximately 50%.
2) The Resistance Competition Assay (RCA), one of two
protocols developed here, uses the change in the frequen-
cy of a minority population of bacteria resistant to the
treating agent as a measure of the efficacy of treatment in
vivo. Our RCA estimates from phage and streptomycin
treatment of E. coli K1 infections in laboratory mice are
consistent with mortality rates. With immediate treat-
ment, the RCA values for the streptomycin and K1-specific
phages (which totally prevented mortality) were both
substantially greater than that of the phage not specific for
the K1 capsule (for which 60% of the treated mice died).
RCA values for the K1-specific phage and for single doses
of streptomycin when treatment was delayed by eight
hours were substantially and significantly less than those
estimated for immediate treatment. The RCA supports
earlier observations that as time between infection and
treatment increases, bacteria become increasingly refrac-
tory to treatment (e.g., because of changes in bacterial
physiological and/or the host environment).BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/35
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3) The Phage Replication Assay (PRA) provides a simple
measure of the rate of replication (and host cell killing) of
lytic phage under defined conditions. By varying those
conditions, it is possible to identify factors that affect
phage growth and hence their efficacy in killing the target
bacteria. Over a wide range of densities of bacteria grow-
ing in artificial medium, the estimated PRAs were similar
between the K1-specific and non-specific phages. Based
on these estimates we would not have anticipated differ-
ent efficacies of these phage in treating E. coli K1 infec-
tions. On the other hand, the assay performed in mouse
serum yielded substantially greater efficacy of the K1-spe-
cific phage, matching its superior performance in the
mouse.
4) The results of this investigation, like those of Smith and
Huggins and others, support the potential of phage for
treating bacterial infections and the development of ex-
perimental infection models to evaluate and optimize the
efficacy of antibiotic as well as phage treatment protocols.
Our results illustrate the value of exploring the dynamics
of the bacterial population during treatment in the evalu-
ation and design of treatment protocols
Methods
Culture and sampling medium and procedures
In vitro, liquid cultures of bacteria and phage were grown
and maintained in Luria – Bertani broth (LB), supple-
mented with 1 gm/l glucose. Bacterial densities were esti-
mated from colony counts on Petri dishes (plates)
containing 25 mL of LB with 1.75% agar. Phage densities
were estimated on these plates with 3 ml top (0.7%) agar
containing LB glucose and 100 ul of an overnight culture
of the bacteria (about 2 × 109 bacteria per ml). When
needed, the bacterial and phage suspensions were serially
diluted in 0.85% saline or LB Glucose before plating.
When rare (less than 10%), phage-resistant bacterial den-
sities were estimated by plating with and without ~109
phage particles in soft agar; when common, they were es-
timated by streaking individual colonies across high den-
sities of phage on plates. A similar selective plating
procedure was used to estimate the densities of antibiotic
resistant bacteria.
Bacteria
The primary strain used in these experiments was CAB1,
an E. coli of the same serotype as that used by Smith and
Huggins [18] (O18:K1:H7), but isolated from a different
source [42]. We also used a TcR, Kps-, E. coli K-12 chimera
of this isolate, designated CAB281, that does not express
the K1 antigen [42].
Phage
Phages were isolated from an Atlanta, Georgia sewage
treatment plant. An aliquot of liquid sewage from the in-
flow to the plant was treated with chloroform to kill bac-
teria and human viruses. The chloroform-free supernatant
was then enriched for E. coli 018:K1:H7-specific phage by
adding 1 ml of this suspension to 10 ml LB containing
CAB1 (approximately 4 × 107 bacteria per ml). These mix-
tures of bacteria and sewage were grown for a minimum
of four hours, mixed with chloroform, and centrifuged to
remove debris. The vast majority of phages in these crude
lysates were able to grow on CAB281 as well as CAB1,
hence were not K1-specific. To enrich for K1-specific
phage, the mixed lysate was incubated with CAB281 and
treated with chloroform 10 minutes later to abort infec-
tions. After removing the chloroform, the cycle was re-
peated 4 times. The phage were then plated with lawns of
CAB1 and single plaques were patched onto lawns of
CAB281. Of the 50 plaques isolated after this passage, two
were from phage that grew on CAB1 but not on CAB281,
hence were presumed to be specific for the K1-capsule.
From these plates, one clone each of a K1-specific and
non-K1 specific phage was chosen, designated φLH and
φLW, respectively.
The two phages were characterized morphologically and
molecularly. Electron micrographs revealed that both had
a B1 morphology [43] similar to phage λ but with a tail of
hexagonal symmetry and a somewhat shorter head-tail
connector than λ. Whole genomes of both phages migrat-
ed in agarose gels at approximately 40 kb; genomes of
φLH and φLW were sensitive to Xmn  I digestion but
showed different digestion patterns.
In vivo experiments
All mouse experiments were conducted at Emory Univer-
sity using protocols approved by the Emory University In-
stitutional Animal Care Committee. All of the in vivo
experiments were performed with female, outbred, white
(Swiss) mice (Harlin Sprague) of from 6 to 10 weeks of
age (22–30 grams). Mice were maintained in cages con-
taining 5 or fewer animals. Using 1 ml tuberculin syringes,
suspensions of bacteria were injected into a mouse thigh.
For treatment, phage lysates, pseudolysates (phage-free
bacterial cultures treated with chloroform), saline or
streptomycin sulfate (SIGMA™) solutions were injected
into the opposite thigh or a forelimb muscle. Although
chloroform was absent from injected lysates and pseu-
dolysates, no other attempts were made to refine these
preparations. Except as noted, the numbers of bacteria
and phage injected were each approximately 108 and the
total volume injected was normally 0.1 ml or less. Follow-
ing the initial inoculation, the infected animals were peri-
odically observed (usually at intervals of less than 12
hours), with more frequent observations (2 hour inter-
vals) made during the 28–40 hour post infection period
when mortality was anticipated. Infected mice surviving
beyond 48 hours never succumbed to the infection in theBMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/35
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next 5 days. In situations where the mouse's ataxic appear-
ance indicated that death was imminent, the mouse was
euthanized.
Samples of bacteria and phage taken from leg muscle were
maintained for a maximum of 1 hour on ice before being
weighed and suspended in 2 ml of saline and homoge-
nized with a Tissue Tearor™. The densities of bacteria and
phage in these homogenates were estimated by diluting
and plating.
Resistance Competition Assay (RCA)
This assay measures the efficacy of phage or streptomycin
in limiting replication by an infecting population of bac-
teria in infected mice. The principle underlying this assay
is that bacteria resistant to a treatment will increase in fre-
quency over sensitive bacteria only to the extent that the
treatment is effective at killing or reducing the rate of
growth of the sensitive bacteria. The assay converts the ad-
vantage of resistance into a measure of treatment efficacy.
For this assay, mice were inoculated with mixtures of 108
bacteria (CAB1) that were sensitive to the treatment
(phage or antibiotics) along with low frequencies (10-2–
10-3) of bacteria resistant to the treatment. The mice were
then treated with phage or streptomycin either immedi-
ately (0 hours) or after a delay of 8 hours, or were inocu-
lated with sterile 0.85% saline (controls). At 3, 4, or 4.5
hours after treatment, the mice were sacrificed and the rel-
ative frequencies resistant bacteria in the mixtures were es-
timated from the homogenized leg tissue. We applied this
assay in two ways: 1) By using different mice for the im-
mediate and delayed treatments or, 2) by inoculating the
same mouse in different hind limb thighs, with the sec-
ond inoculation delayed 8 hours, and treating the mouse
immediately by inoculation of streptomycin, phage or sa-
line into the musculature of a forelimb
Phage Replication Assay (PRA)
This procedure estimates in vitro the potential therapeutic
efficacy of phages. It simply measures the rate at which a
phage population increases in density (its rate of replica-
tion) when grown on a strain of bacteria under prescribed,
controlled conditions. Phage replication in vivo is pre-
sumed to be an integral part of phage therapy success, so
to the extent that replication in vitro mirrors replication in
vivo, this assay should indicate which phages are the best
choices for therapy. The rate of replication of φLH and
φLW on CAB1 was measured in LB and in mouse serum.
Assays in LB were conducted as follows. The bacteria were
grown with aeration in LB at 37° until reaching a specified
density as measured by light scattering from a side-arm
flask. Glucose and calcium were not added to the LB in
these assays. Aliquots of 1 ml of the growing bacterial cul-
tures were added to empty tubes along with the phage.
The suspensions were grown for 1 hr at which time chlo-
roform was added. Assays in mouse serum were conduct-
ed similarly, except that the densities at the time the phage
were added were determined by plating and thus could
not be standardized between replicates. The bacteria were
allowed to replicate in serum for at least 2 hours before
addition of phage. Phage concentrations were determined
at the beginning and end points to calculate a per-capita
increase ratio, ρ; we then transformed this value to log2(ρ)
to estimate of the number of doublings per hour (see the
Additional file 1 for the sensitivity of this measure).
Several precautions were taken to avoid biases and reduce
the error in estimating ρ. Phage concentrations were
maintained at low levels throughout the assay so that un-
infected cells did not become limiting (the final phage
density was never greater than the cell density, indicating
that a majority of cells remained uninfected during the as-
say period). To reduce sources of variance in growth rate
extrinsic to the phages, growth rate assays of both phages
were usually conducted simultaneously with aliquots of
the same parent culture for both phages.
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